Galectin Therapeutics Inc.
GALT
$2.41
$0.010.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.67% | -1.14% | -3.30% | -4.68% | -5.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -60.02% | -52.67% | -26.33% | -14.24% | 8.84% |
| Operating Income | 60.02% | 52.67% | 26.33% | 14.24% | -8.84% |
| Income Before Tax | 41.91% | 34.46% | 17.25% | 8.91% | -10.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 41.91% | 34.46% | 17.25% | 8.91% | -10.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.91% | 34.46% | 17.25% | 8.91% | -10.14% |
| EBIT | 60.02% | 52.67% | 26.33% | 14.24% | -8.84% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 43.29% | 35.90% | 18.81% | 17.81% | 1.82% |
| Normalized Basic EPS | 43.53% | 35.98% | 18.85% | 10.93% | -7.00% |
| EPS Diluted | 43.29% | 35.90% | 18.81% | 17.81% | 1.82% |
| Normalized Diluted EPS | 43.53% | 35.98% | 18.85% | 10.93% | -7.00% |
| Average Basic Shares Outstanding | 3.08% | 2.55% | 2.11% | 2.40% | 3.02% |
| Average Diluted Shares Outstanding | 3.08% | 2.55% | 2.11% | 2.40% | 3.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |